Table 1. First-line treatment... | American Society of Hematology

Table 1.

First-line treatment trials/series in “young fit” CLL

Regimen	Trial	No. of patients	Median age, y	CR %	ORR %	Median PFS, mo	PFS in mutated IGHV	PFS in unmutated IGHV
FCR	MDACC^4-6	300	57	72	95	77	80% at 5 y	45% at 5 y
	MDACC^4-6	300	57	72	95	77	55% at 10 y	10% at 10 y
	GCLLSG CLL8^7,18	408	61	44	90	52	67% at 5 y	33% at 5 y
	GCLLSG CLL10⁹	282	61	40	95	55	75% at 4 y	45% at 4 y
	Italian retrospective series¹⁹	404	—	—	—	55	60% at 5 y	35% at 5 y
BR	GCLLSG CLL10⁹	279	62	31	96	42	65% at 4 y	25% at 4 y

Regimen	Trial	No. of patients	Median age, y	CR %	ORR %	Median PFS, mo	PFS in mutated IGHV	PFS in unmutated IGHV
FCR	MDACC^4-6	300	57	72	95	77	80% at 5 y	45% at 5 y
	MDACC^4-6	300	57	72	95	77	55% at 10 y	10% at 10 y
	GCLLSG CLL8^7,18	408	61	44	90	52	67% at 5 y	33% at 5 y
	GCLLSG CLL10⁹	282	61	40	95	55	75% at 4 y	45% at 4 y
	Italian retrospective series¹⁹	404	—	—	—	55	60% at 5 y	35% at 5 y
BR	GCLLSG CLL10⁹	279	62	31	96	42	65% at 4 y	25% at 4 y

—, not reported; ORR, overall response rate.